Neo-Natal Hypoxia
In utero cannabinoid exposure alters breathing and the response to hypoxia in newborn mice
Keda C. Tree, Maud Scotto di Perretolo, Julie Peyronnet, Florence Cayetanot (April 2014)
Cannabis is one of the most commonly used recreational drugs at ages highly correlated with potential pregnancy. Endocannabinoid signalling regulates important stages of neuronal development. When cannabinoid receptors, which are widely distributed through the nervous system, are activated by exogenous cannabinoids, breathing in adult rats is depressed. Here, we show that, in newborn mice, endocannabinoids, through the activation of cannabinoid receptor type 1 (CB1R), participate in the modulation of respiration and its control.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.
Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets
Francisco J. Alvarez, Hector Lafuente, M. Carmen Rey-Santano, Victoria E. Mielgo, Elena Gastiasoro, Miguel Rueda, Roger G. Pertwee, Ana I. Castillo, Julian Romero and Jose Martinez-Orgado (July 2008)
The aim of the present work was to study the neuroprotective effect of CBD by using the temporary occlusion of both carotid arteries combined with hypoxia animal model, considered as very close to actual perinatal asphyxia in human neonates (12). In addition, we aimed to test the protective effect of CBD by using the two best devices available for actual bedside studies in asphyxiated newborns: near-infrared spectroscopy (NIRS), a noninvasive optical technique for assessing circulation and oxygenation in brain, and amplitudeintegrated electroencephalography (aEEG). Neuroprotection by CBD was also assessed by histologic study. Finally, we also aimed to test whether CBD administration was free of significant clinical side effects.
Important Notice
If you proceed to article you will be leaving the CB1 Capital Management website to access a website hosted by a party unrelated to CB1 Capital Management. CB1 Capital Management assumes no responsibility for the accuracy of any of these studies nor does CB1 assume any obligation to update any of these studies based on subsequent research.